Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

ALLERGAN, INC. (AGN)

42
Delayed Quote. Delayed Nyse - 11/21 04:00:12 pm
209.09 USD   -0.53%
1d ago ALLERGAN : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigatio..
1d ago Valeant slashes stake in Allergan after losing bid
1d ago Global M&A lending hits post-crisis high
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Allergan, Inc. : Allergan : Studies Show Botox Treats Overactive Bladder

03/28/2012 | 09:54am US/Eastern

Allergan Inc. (AGN) filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladder as two Phase III clinical trials showed the injectible neurotoxin significantly reduced urinary incontinence when compared with a placebo.

Botox is approved for both cosmetic use, such as fighting wrinkles, and for various medical issues, including urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan on Wednesday said Botox met the primary endpoints of significantly reducing urinary incontinence, or bladder leakage, episodes in patients who have an inadequate response to or are intolerant of an anticholinergic medication.

Based on the results, Allergan has submitted a supplemental biologics license application with the U.S. Food and Drug Administration and an application with European Regulatory authorities to approve the use of Botox by adult patients not managed by an anticholinergic treatment.

The drug maker has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (MAPP) to jointly promote Map's experimental migraine treatment Levadex.

Allergan reported last month its fourth-quarter earnings rose 6.3% as higher specialty pharmaceuticals sales contributed to a 7.1% revenue jump.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

React to this article
Latest news on ALLERGAN, INC.
1d ago ALLERGAN : SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of ..
1d ago ALLERGAN : $66B Actavis-Allergan deal, Cantel Medical leadership appointment & m..
1d ago Valeant slashes stake in Allergan after losing bid
1d ago Global M&A lending hits post-crisis high
1d ago Global M&A deals cross $3 trillion for first time since 2007
1d agoDJU.S. Stock Futures Rally on China, Draghi
2d ago Valeant slashes stake in Allergan after losing bid
2d ago Valeant Pharma says may buy back up to $2 billion worth of securities
2d agoDJValeant Sets $2 Billion Buyback Plan After Losing Allergan
2d ago MEGA MERGERS : Wall Street sees $100bn deals
Advertisement
Chart
Duration : Period :
Allergan, Inc. Technical Analysis Chart | AGN | US0184901025 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF